Experts hail highly successful trial of Lilly's cholesterol-busting drug lepodisiran
Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...
Deadly cholesterol that doesn’t show up on routine tests is slashed by 94% with single dose of new drug
This is a major source of cardiovascular morbidity and mortality. We have never been able to treat lipoprotein(a) until now.” ...
BioPharma Dive3d
Lilly study data reinforce potential of new kind of heart drug
Drugs from Novartis, Amgen and now Lilly have proven powerfully effective at reducing Lp(a). Whether that will translate to a ...
pharmaphorum3d
ACC25: Positive results with Lilly's Lp(a)-lowering drug
Eli Lilly's gene-silencing drug lepodisiran has been shown to reduce lipoprotein (a) levels by more than 90% for at least six ...
Healio4d
Lepodisiran lowers Lp(a) substantially with infrequent administration
CHICAGO — Lepodisiran, a small interfering RNA agent, lowered lipoprotein(a) levels at 180 days, with a reduction of more ...
BioSpace3d
Lilly’s RNA Silencer Lowers Key Cardiovascular Biomarker by Almost 94%
BMO Capital Markets analysts said the results potentially position lepodisiran as “one of the most durable assets in ...
PharmiWeb3d
Lilly's lepodisiran reduced levels of genetically…
Eli Lilly and Company (NYSE: LLY) today announced positive Phase 2 results for lepodisiran, an investigational small interfering RNA (siRNA) therapy designed to lower the production of lipoprotein(a) ...